N-(4-(2-Hexylhydrazine-1-carbonyl)benzyl)benzamide

ID: ALA4740950

PubChem CID: 139558698

Max Phase: Preclinical

Molecular Formula: C21H27N3O2

Molecular Weight: 353.47

Molecule Type: Unknown

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  CCCCCCNNC(=O)c1ccc(CNC(=O)c2ccccc2)cc1

Standard InChI:  InChI=1S/C21H27N3O2/c1-2-3-4-8-15-23-24-21(26)19-13-11-17(12-14-19)16-22-20(25)18-9-6-5-7-10-18/h5-7,9-14,23H,2-4,8,15-16H2,1H3,(H,22,25)(H,24,26)

Standard InChI Key:  BXHBEDYMTAULCE-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 27  0  0  0  0  0  0  0  0999 V2000
    9.4248  -15.3230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7194  -14.9151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7186  -14.0979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0091  -13.6900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3004  -14.0993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3013  -14.9165    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0108  -15.3244    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4256  -16.1402    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.1335  -14.9137    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.8389  -15.3216    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5475  -14.9123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2570  -15.3243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9616  -14.9150    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9608  -14.0978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2554  -13.6899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5467  -14.0951    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6695  -13.6885    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6686  -12.8713    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.3790  -14.0964    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.0876  -13.6871    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.0868  -12.8699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7914  -12.4606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7947  -11.6434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4992  -11.2341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4984  -10.4169    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.2071  -10.0076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  2  7  2  0
  1  8  2  0
  1  9  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 11 16  2  0
 17 18  2  0
 19 20  1  0
 17 19  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 20 21  1  0
 14 17  1  0
  9 10  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4740950

    ---

Associated Targets(Human)

HDAC3 Tclin Histone deacetylase 3 (3654 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 353.47Molecular Weight (Monoisotopic): 353.2103AlogP: 3.43#Rotatable Bonds: 10
Polar Surface Area: 70.23Molecular Species: NEUTRALHBA: 3HBD: 3
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 3.90CX LogP: 3.76CX LogD: 3.76
Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.45Np Likeness Score: -0.89

References

1. McClure JJ,Zhang C,Inks ES,Peterson YK,Li J,Chou CJ.  (2016)  Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.,  59  (21): [PMID:27754681] [10.1021/acs.jmedchem.6b01385]

Source